Ireland
--:--IST
Starting soon Observational

Endoscopic vs Non-endoscopic Drainage for Benign Gallbladder Diseases in High-risk Patients or Patients Desiring Gallbladder Preservation

NCT07649811 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2026-07-01
Last updated
2026-06-16

Condition(s) studied

Gallbladder DiseasesCholecystitis, AcuteCholelithiasis

Investigational drug(s) / intervention(s)

Endoscopic Gallbladder DrainagePercutaneous Gallbladder Drainage

Endoscopic Gallbladder Drainage: Minimally invasive drainage of the gallbladder using endoscopic techniques, which may be followed by elective transoral stone removal.

Percutaneous Gallbladder Drainage: Traditional non-endoscopic, percutaneous transhepatic drainage of the gallbladder, typically involving long-term passive drainage.

Study summary

Common gallbladder conditions like gallstones, polyps, and gallbladder inflammation are typically treated by surgically removing the gallbladder. However, surgery may be too risky for elderly patients or those with severe medical conditions, and some patients strongly prefer to keep their gallbladder.

Newer, less-invasive endoscopic treatments can drain the gallbladder to treat inflammation without surgery. However, after successful drainage, doctors currently do not know whether it is better to leave a stent inside for long-term drainage or to actively remove the gallbladder stones using an endoscope.

This multicenter study will follow patients in a real-world setting to compare these two approaches: the endoscopic treatment group (stone removal after drainage) and the non-endoscopic treatment group (long-term drainage alone). The goal is to evaluate which method is safer and more effective over the long term, helping doctors make better clinical decisions and improve patients' quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years, and voluntarily signed the informed consent form; * Radiologically confirmed symptomatic benign gallbladder disease (symptomatic gallbladder stones, gallbladder polyps meeting surgical indications, acute cholecystitis TG18 Grade I/II); and meeting any of the following specific population criteria: 1. High-risk surgical patients: ASA classification ≥ III, or presence of severe comorbidities that significantly increase the risk of laparoscopic cholecystectomy (LC); 2. Patients with concomitant common bile duct stones (CBDS) and a strong desire for gallbladder preservation: presence of CBDS confirmed by MRCP/ERCP examination, and still strongly requesting the preservation of gallbladder function after being fully informed. Exclusion Criteria: * Suspected or confirmed gallbladder malignancy; * Complications requiring emergency surgical intervention (gangrene, perforation, diffuse peritonitis); * Uncorrectable severe coagulation dysfunction; * Presence of severe anatomical deformity or obstruction of the stomach, duodenum, or esophagus, where the endoscope is expected to be unable to reach the target site (papilla or pericholecystic area); * Significant gallbladder atrophy (longitudinal diameter \< 4 cm or anteroposterior diameter \< 2 cm); * Pregnant or lactating women; * Previous history of cholecystectomy; * Presence of psychiatric disorders or any condition that prevents cooperation with treatment and follow-up; * Unwilling or unable to sign the informed consent form.

Primary outcome measure(s)

  • Incidence of Overall Adverse Events — Up to 1 year after the initial drainage procedure
    Adverse events related to the drainage procedure and subsequent treatments, including but not limited to bleeding, infection, bile leak, pancreatitis, and stent-related complications.

Trial sites (1)

FacilityCityRegionStatus
Xijing Hospital of Digestive Diseases Xi'an Shaanxi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07649811 on ClinicalTrials.gov ↗ ← All trials in China